drugset / Trial / NCT05455294

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

NCT05455294

Phase 1 Active not recruiting 16 enrolled Jacqueline Garcia, MD AbbVie · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies. The names of the drugs involved in this study are: * Venetoclax * Decitabine * Navitoclax

Timeline

Start
2022-07-18
Primary completion
2024-04-17
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule Intravenous
Subject Navitoclax Small molecule Oral
Subject Venetoclax Small molecule Oral